Literature DB >> 25586345

Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients.

Farzad Maroofi1, Sabrieh Amini, Daem Roshani, Bayazid Ghaderi, Mohammad Abdi.   

Abstract

Finding the effects of gene polymorphism on cancer pathogenesis is very desirable. The ATP-binding cassette is involved in drug metabolism, and the polymorphism of this gene may be an important risk factor in B cell chronic lymphocytic leukemia (B-CLL) or progression and/or response to chemotherapy agents. For the first time, the present study was aimed to evaluate the probable effects of ABCB1 T3435C polymorphism on clinical and laboratory features of Kurdish patients with B-CLL. This descriptive analytical case-control study was performed on 50 B-CLL patients and 100 healthy subjects. Serum levels of beta-2-microglobulin (B2M) and lactate dehydrogenase (LDH) and blood WBC, RBC, Plt and ESR were measured. The T3435C polymorphism of the ABCB1 gene was determined by PCR-RFLP. Concentration of serum and blood markers was significantly higher in the malignant group than in the benign subjects. The CC genotype had the highest frequency (66%) in the patient groups. There are no significant differences between the genotypes and type of treatment. Our results demonstrate the high frequency of C allele of ABCB1 T3435C in B-CLL patients with Kurdish ethnicity. We also show that this polymorphism has a significant risk factor in B-CLL. However, the effect of this polymorphism on clinical and laboratory characteristics of B-CLL patients was not significant.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25586345     DOI: 10.1007/s13277-014-2914-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

Review 1.  Is there evidence to claim or deny association between variants of the multidrug resistance gene (MDR1 or ABCB1) and inflammatory bowel disease?

Authors:  Elias Zintzaras
Journal:  Inflamm Bowel Dis       Date:  2011-09-01       Impact factor: 5.325

Review 2.  Update on risk-stratified management for chronic lymphocytic leukemia.

Authors:  Clive S Zent; Timothy G Call; William J Hogan; Tait D Shanafelt; Neil E Kay
Journal:  Leuk Lymphoma       Date:  2006-09

3.  A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease.

Authors:  D Rund; I Azar; O Shperling
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

Review 4.  P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.

Authors:  Albert Breier; Miroslav Barancík; Zdenka Sulová; Branislav Uhrík
Journal:  Curr Cancer Drug Targets       Date:  2005-09       Impact factor: 3.428

5.  Multi-drug resistance in chronic lymphocytic leukemia.

Authors:  W R Friedenberg; S K Spencer; C Musser; T F Hogan; K A Rodvold; D A Rushing; J J Mazza; D A Tewksbury; J J Marx
Journal:  Leuk Lymphoma       Date:  1999-06

6.  MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders.

Authors:  M Webb; M Brun; M McNiven; D Le Couteur; P Craft
Journal:  Br J Haematol       Date:  1998-08       Impact factor: 6.998

7.  The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.

Authors:  S Gill; D Carney; D Ritchie; M Wolf; D Westerman; H M Prince; H Januszewicz; J F Seymour
Journal:  Ann Oncol       Date:  2009-07-22       Impact factor: 32.976

8.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

Review 9.  MDR1 gene polymorphisms and clinical relevance.

Authors:  Yan-Hong Li; Yong-Hua Wang; Yan Li; Ling Yang
Journal:  Yi Chuan Xue Bao       Date:  2006-02

10.  PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia.

Authors:  C F Rochlitz; E de Kant; A Neubauer; I Heide; R Böhmer; J Oertel; D Huhn; R Herrmann
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

View more
  4 in total

1.  Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.

Authors:  Hana Salimizand; Sabrieh Amini; Mohammad Abdi; Bayazid Ghaderi; Namam-Ali Azadi
Journal:  Tumour Biol       Date:  2015-08-07

2.  Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.

Authors:  Houshiyar Ghafouri; Bayazid Ghaderi; Sabrieh Amini; Bahram Nikkhoo; Mohammad Abdi; Abdolhakim Hoseini
Journal:  Tumour Biol       Date:  2015-12-23

3.  Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues.

Authors:  Chiya Jalali; Bayazid Ghaderi; Sabrieh Amini; Mohammad Abdi; Daem Roshani
Journal:  Saudi Med J       Date:  2016-06       Impact factor: 1.484

4.  Higher risk of progressing breast cancer in Kurdish population associated to CDH1 -160 C/A polymorphism.

Authors:  Farzaneh Zarei; Mohammad Nazir Menbari; Bayazid Ghaderi; Mohammad Abdi; Zakaria Vahabzadeh
Journal:  EXCLI J       Date:  2017-11-06       Impact factor: 4.068

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.